Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Prompt recognition and treatment initiation are paramount in acute promyelocytic leukemia cases presenting with fever, weakness, and pancytopenia, as highlighted in this clinical analysis.
Hematology/Oncology May 6th 2024
In a recent study involving patients with CD7-positive leukemia and lymphoma, an integrated approach of CAR T-cell therapy followed by haploidentical HSCT resulted in a one-year disease-free survival rate of 54%. This strategy highlights the potential for advanced therapeutic combinations to manage relapsed or refractory hematologic cancers effectively.
Hematology/Oncology April 29th 2024
Annals of Internal Medicine
This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.
Hematology/Oncology April 8th 2024
OBR Oncology
Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.
Clinical Advances in Hematology & Oncology
Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.
Hematology/Oncology March 18th 2024
With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.
Hematology/Oncology February 5th 2024